Best Income Stocks to Buy for September 25th
Source: zacks.com

Zacks highlighted HP, Cricut and Provident Financial Holdings as income-stock candidates, supported by upward revisions to current-year earnings estimates. Consensus EPS estimates rose 8.4% for HP over 60 days, 128.6% for Cricut and 17.3% for Provident Financial Holdings. The item is a bullish stock-screening recommendation rather than company-reported results or a material corporate development.
Analysis
This is low-information, promotional research rather than a fundamental catalyst; the estimate revisions may reflect stale consensus mechanics and should not be treated as evidence of incremental demand. The modest near-term implication is a potential retail-flow bid in HPQ and CRCT, but neither has sufficient liquidity or institutional relevance for a durable rerating without earnings confirmation. PROV is particularly unsuitable as a signal: thin regional-bank liquidity can amplify small flows while masking meaningful duration, deposit-cost, and commercial-real-estate exposure.
HPQ is the most actionable name only as a relative-value expression. Its cash-return profile can support the stock if PC replacement demand and printing consumables remain resilient, but upside is constrained by secular print pressure and AI-PC expectations already embedded in the broader hardware narrative. A 1-3 month catalyst requires a further upward revision to units, gross margin, or free-cash-flow guidance; absent that, the likely outcome is yield-oriented range trading rather than multiple expansion.
CRCT's unusually large estimate-change percentage is more likely a low-base denominator effect than validation of a structural growth inflection. The key issue over 6-18 months is whether paid-subscriber retention and machine attach rates improve without elevated marketing spend; otherwise, earnings upside can be offset by weaker revenue quality and inventory volatility. The contrarian read is that public estimate-revision screens attract late retail buyers precisely when the revision cycle is mature, creating a better fade than momentum setup if the stocks gap on publication.
For banks, PROV should be assessed through the same rate-sensitive lens as PFS, but with greater single-name liquidity risk. A declining-rate cycle can relieve funding costs over several quarters, yet rapid cuts may also compress asset yields and expose credit normalization; quarterly net-interest-margin guidance and deposit beta matter more than generic income-stock positioning.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
Key Decisions for Investors
- No directional trade solely on the publication; treat any same-day HPQ or CRCT strength as a sentiment event, not a fundamentals catalyst.
- Watch HPQ for a 1-3 month tactical long only after earnings confirm higher PC units or raise free-cash-flow guidance; target 8-12% upside versus a 5% stop if guidance is unchanged or printing revenue deteriorates.
- If CRCT rallies more than 10% without evidence of subscriber growth, repeat-purchase improvement, and stable marketing intensity, consider a small 1-2 month short or put spread; cover on a material revenue-guide increase or demonstrated recurring-revenue acceleration.
- Avoid PROV as a new position until deposit concentration, CRE exposure, and daily liquidity are verified. For a liquid regional-bank rate view, use PFS as a watch proxy and reassess after its next NIM/deposit-beta update.
More News
- Can Freeport-McMoRan's Growth Projects Drive the Next Expansion Wave?
- Rigetti, D-Wave, or IonQ: Which Quantum Stock Has the Best Shot at Survival?
- Micron vs. NVIDIA: 1 AI Stock to Buy Now and 1 to Watch
- 3 Stocks in Focus That Declared Dividend Hikes Amid Economic Woes
- TD SYNNEX Q3 Earnings Beat Estimates on Distribution and Hyve Strength
- RCL's $3B Sandals Bet Sparks Market Buzz: Is the Stock a Buy?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework